InsiderTrades.com logo
Your Money is Not Safe
From American Alternative   |   Ad
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
CLICK HERE TO GET YOUR GUIDE NOW
Daniel Gruskin net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Daniel Gruskin Biography and Net Worth

Insider of LogicBio Therapeutics
Daniel Gruskin was promoted to chief medical officer in May 2021. He was named senior vice president and head of clinical development in August of 2020 after several months working with LogicBio as interim head of clinical development and as a consultant. Previously, Daniel served in roles of increasing responsibility at Sanofi Genzyme, most recently as vice president, head of global medical affairs, rare disease, in which capacity he oversaw medical affairs, life cycle management, scientific affairs and other medical and development activities related to metabolic, rare and/or genetic diseases. Prior to his role at Sanofi Genzyme, Daniel served as assistant professor, human genetics and pediatrics at Emory University School of Medicine, where he was also the chief of the genetics section at Children’s Healthcare of Atlanta.

What is Daniel Gruskin's net worth?

The estimated net worth of Daniel Gruskin is at least $9,931.86 as of August 9th, 2021. Dr. Gruskin owns 4,798 shares of LogicBio Therapeutics stock worth more than $9,932 as of April 20th. This net worth approximation does not reflect any other investments that Dr. Gruskin may own. Additionally, Dr. Gruskin receives a salary of $577,480.00 as Insider at LogicBio Therapeutics. Learn More about Daniel Gruskin's net worth.

How old is Daniel Gruskin?

Dr. Gruskin is currently 50 years old. There are 5 older executives and no younger executives at LogicBio Therapeutics. The oldest executive at LogicBio Therapeutics is Dr. Mark A. Kay M.D., Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director, who is 64 years old. Learn More on Daniel Gruskin's age.

What is Daniel Gruskin's salary?

As the Insider of LogicBio Therapeutics, Inc., Dr. Gruskin earns $577,480.00 per year. The highest earning executive at LogicBio Therapeutics is Mr. Frederic Chereau M.B.A., Pres, CEO & Director, who commands a salary of $793,200.00 per year. Learn More on Daniel Gruskin's salary.

How do I contact Daniel Gruskin?

The corporate mailing address for Dr. Gruskin and other LogicBio Therapeutics executives is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. LogicBio Therapeutics can also be reached via phone at (617) 245-0399 and via email at [email protected]. Learn More on Daniel Gruskin's contact information.

Has Daniel Gruskin been buying or selling shares of LogicBio Therapeutics?

Daniel Gruskin has not been actively trading shares of LogicBio Therapeutics during the last ninety days. Most recently, Daniel Gruskin sold 1,467 shares of the business's stock in a transaction on Monday, August 9th. The shares were sold at an average price of $4.35, for a transaction totalling $6,381.45. Following the completion of the sale, the insider now directly owns 4,798 shares of the company's stock, valued at $20,871.30. Learn More on Daniel Gruskin's trading history.

Who are LogicBio Therapeutics' active insiders?

LogicBio Therapeutics' insider roster includes Frederic Chereau (Insider), Kyle Chiang (COO), and Daniel Gruskin (Insider). Learn More on LogicBio Therapeutics' active insiders.

Daniel Gruskin Insider Trading History at LogicBio Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2021Sell1,467$4.35$6,381.454,798View SEC Filing Icon  
See Full Table

Daniel Gruskin Buying and Selling Activity at LogicBio Therapeutics

This chart shows Daniel Gruskin's buying and selling at LogicBio Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

LogicBio Therapeutics Company Overview

LogicBio Therapeutics logo
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $2.07
Low: $2.07
High: $2.07

50 Day Range

MA: $2.06
Low: $2.04
High: $2.07

2 Week Range

Now: $2.07
Low: $0.26
High: $3.77

Volume

N/A

Average Volume

652,526 shs

Market Capitalization

$68.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.61
Your Money is Not Safe
From American Alternative   |   Ad
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
CLICK HERE TO GET YOUR GUIDE NOW